Dose escalation phase (titration) Tirzepatide titration (dose escalation) typically follows this schedule: Month 2: 4-6 mg once weekly Month 3: 6-8 mg once weekly Month 4: If tolerated, increase to 8-10 mg once weekly Month 5: If the dosage needs to be escalated further, increase to 10-12 mg once weekly Month 6 and onward: If the dosage needs to be escalated further, increase to 12-14 mg once weekly The maximum dosage is typically 14 mg once weekly if further glycemic control or weight loss is required
Growth Hormone Releasing Peptides (GHRPs) Growth hormone releasing peptides (GHRPs) stimulate the release of growth hormone, supporting metabolism, fat loss, and muscle maintenance
Anti-Inflammatory and Cytokine Regulation BPC-157 downregulates pro-inflammatory mediators including: Tumor Necrosis Factor-Alpha (TNF-) Interleukin-1 Beta (IL-1) Interleukin-6 (IL-6) Leukotrienes key drivers of pain and inflammation in arthritis and tendinopathy Growth Hormone Receptor Upregulation Emerging research suggests BPC-157 increases growth hormone receptor density in injured tissues, amplifying the natural repair signals that decline with age or chronic inflammation
Why Researchers Choose Cenexa Labs End-to-End Chain of Custody : Every batch is logged, tested, and traceable no middlemen, no relabeling, no guesswork